An Investigation into the Cost of Unit Testing on an Embedded System

The quality of embedded software is important, especially for life-critical and mission-critical embedded systems. And software testing is a key activity to ensure the quality of embedded software. Both system testing and unit testing are vital to test embedded software. Unit testing is probably more important to ensure there are no latent faults. System testing is almost invariably done on a target system, but unit testing is normally done on a host system, as standard test frameworks generally don’t support the execution of unit tests on a target system. This paper analyzes the significant quality benefits to run unit testing on a target system. Also, it presents a performance model for evaluating the test execution cost, discusses the experimental results, and identifies the factors which influence the experimen

An Investigation into the Cost of Unit Testing on an Embedded System

The quality of embedded software is important, especially for life-critical and mission-critical embedded systems. And software testing is a key activity to ensure the quality of embedded software. Both system testing and unit testing are vital to test embedded software. Unit testing is probably more important to ensure there are no latent faults. System testing is almost invariably done on a target system, but unit testing is normally done on a host system, as standard test frameworks generally don’t support the execution of unit tests on a target system. This paper analyzes the significant quality benefits to run unit testing on a target system. Also, it presents a performance model for evaluating the test execution cost, discusses the experimental results, and identifies the factors which influence the experimen

An Investigation into the Cost of Unit Testing on an Embedded System

The quality of embedded software is important, especially for life-critical and mission-critical embedded systems. And software testing is a key activity to ensure the quality of embedded software. Both system testing and unit testing are vital to test embedded software. Unit testing is probably more important to ensure there are no latent faults. System testing is almost invariably done on a target system, but unit testing is normally done on a host system, as standard test frameworks generally don’t support the execution of unit tests on a target system. This paper analyzes the significant quality benefits to run unit testing on a target system. Also, it presents a performance model for evaluating the test execution cost, discusses the experimental results, and identifies the factors which influence the experimen

An Investigation into the Cost of Unit Testing on an Embedded System

The quality of embedded software is important, especially for life-critical and mission-critical embedded systems. And software testing is a key activity to ensure the quality of embedded software. Both system testing and unit testing are vital to test embedded software. Unit testing is probably more important to ensure there are no latent faults. System testing is almost invariably done on a target system, but unit testing is normally done on a host system, as standard test frameworks generally don’t support the execution of unit tests on a target system. This paper analyzes the significant quality benefits to run unit testing on a target system. Also, it presents a performance model for evaluating the test execution cost, discusses the experimental results, and identifies the factors which influence the experimen

An Investigation into the Cost of Unit Testing on an Embedded System

The quality of embedded software is important, especially for life-critical and mission-critical embedded systems. And software testing is a key activity to ensure the quality of embedded software. Both system testing and unit testing are vital to test embedded software. Unit testing is probably more important to ensure there are no latent faults. System testing is almost invariably done on a target system, but unit testing is normally done on a host system, as standard test frameworks generally don’t support the execution of unit tests on a target system. This paper analyzes the significant quality benefits to run unit testing on a target system. Also, it presents a performance model for evaluating the test execution cost, discusses the experimental results, and identifies the factors which influence the experimen

Investigating Pre-eruptive Magnetic Properties at the Footprints of Erupting Magnetic Flux Ropes

It is well established that solar eruptions are powered by free magnetic energy stored in the current-carrying magnetic field in the corona. It has also been generally accepted that magnetic flux ropes (MFRs) are a critical component of many coronal mass ejections. What remains controversial is whether MFRs are present well before the eruption. Our aim is to identify progenitors of MFRs, and investigate pre-eruptive magnetic properties associated with these progenitors. Here we analyze 28 MFRs erupting within 45° from the disk center from 2010 to 2015. All MFRs’ feet are well identified by conjugate coronal dimmings. We then calculate the magnetic properties at the feet of the MFRs, prior to their eruptions, using Helioseismic and Magnetic Imager vector magnetograms. Our results show that only 8 erupting MFRs are associated with significant nonneutralized electric currents, 4 of which also exhibit pre-eruptive dimmings at the footprints. Twist and current distributions are asymmetric at the two feet of these MFRs. The presence of pre-eruption dimmings associated with nonneutralized currents suggests the preexisting MFRs. Furthermore, the evolution of conjugate dimmings and electric currents within the footprints can provide clues about the internal structure of MFRs and their formation mechanism

Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215)Research in context

Summary: Background: Immunotherapy has revolutionized the treatment of cancer. However, microsatellite stable (MSS) metastatic colorectal cancer (mCRC) shows a low response to PD-1 inhibitors. Antiangiogenic therapy can enhance anti-PD-1 efficacy, but it still cannot meet clinical needs. Increasing evidence supported a close relationship between gut microbiome and anti-PD-1 efficacy. This study aimed to explore the efficacy and safety of the combination of fecal microbiota transplantation (FMT) and tislelizumab and fruquintinib in refractory MSS mCRC. Methods: In the phase II trial, MSS mCRC patients were administered FMT plus tislelizumab and fruquintinib as a third-line or above treatment. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall survival (OS), objective response rate (ORR), disease control rate (DCR), duration of response (DoR), clinical benefit rate (CBR), safety and quality of life. Feces and peripheral blood were collected for exploratory biomarker analysis. This study is registered with Chictr.org.cn, identifier ChiCTR2100046768. Findings: From May 10, 2021 to January 17, 2022, 20 patients were enrolled. Median follow-up was 13.7 months. Median PFS was 9.6 months (95% CI 4.1–15.1). Median OS was 13.7 months (95% CI 9.3–17.7). Median DoR was 8.1 months (95% CI 1.7–10.6). ORR was 20% (95% CI 5.7–43.7). DCR was 95% (95% CI 75.1–99.9). CBR was 60% (95% CI 36.1–80.9). Nineteen patients (95%) experienced at least one treatment-related adverse event (TRAE). Six patients (30%) had grade 3–4 TRAEs, with the most common being albuminuria (10%), urine occult blood (10%), fecal occult blood (10%), hypertension (5%), hyperglycemia (5%), liver dysfunction (5%), hand-foot skin reaction (5%), and hypothyroidism (5%). No treatment-related deaths occurred. Responders had a high-abundance of Proteobacteria and Lachnospiraceae family and a low-abundance of Actinobacteriota and Bifidobacterium. The treatment did not change the structure of peripheral blood TCR repertoire. However, the expanded TCRs exhibited the characteristics of antigen-driven responses in responders. Interpretation: FMT plus tislelizumab and fruquintinib as third-line or above treatment showed improved survival and manageable safety in refractory MSS mCRC, suggesting a valuable new treatment option for this patient population. Funding: This study was supported by the National Natural Science Foundation of China (82102954 to Wensi Zhao) and the Special Project of Central Government for Local Science and Technology Development of Hubei Province (ZYYD2020000169 to Yongshun Chen)